Faced with increasing demands for safety and responsiveness, how can the production of complex medicines be guaranteed without fail? Delpharm asserts itself as a leading strategic partner, turning every pharmaceutical challenge into an industrial success thanks to a network of high-performance sites. This journey into the heart of pharmaceutical excellence reveals cutting-edge solutions, combining rigorous technical mastery with a sincere commitment to a sustainable future.
- Delpharm and mastery of various dosage forms
- An industrial network serving performance
- Regulatory rigor and lifecycle management
- Towards a responsible and connected industry
📍 My experience: During a visit to an industrial site last year, I was struck by the complexity of bottling sterile solutions. A simple calibration error can cost tens of thousands of euros in active ingredient losses. The lesson I learned is that a CDMO’s technical expertise is not limited to machines but lies in the precision of human protocols.
Delpharm and mastery of various dosage forms
✅ Strengths
- Control of production costs
- Access to rare technologies
- Strict compliance with GMP standards
🔍 Limitations
- Dependence on site scheduling
- Complexity of initial transfer
After setting the scene of the current pharmaceutical industry, let’s directly address the core business of Delpharm: its ability to transform a formula into a finished product.
Physical form of a medicine designed for its mode of administration.
The versatility of solid and liquid forms
The group ensures mass production of tablets and capsules. This expertise is based on mastery of granulation and compression. Each unit guarantees exemplary consistency.
The offer extends to liquids such as syrups. Managing mixtures is crucial. Delpharm precisely controls the viscosity of each drinkable solution.
These products comply with international standards. This allows for smooth export to global markets. Regulatory compliance remains an absolute priority.
To go deeper, I recommend you consult my article on storage and environment which complements this industrial topic well. The guide on billing software also provides useful leads for managing the administrative part. And to go further, discovering the house of nature offers an interesting insight into current ecological issues.
The technical requirements of sterile and semi-solid products
The manufacture of injectables requires rigorous aseptic environments. Each step guarantees safety. This process protects the patient’s integrity.
For ointments, the know-how is unique. Delpharm ensures the stability of dermatological emulsions. The texture remains perfectly homogeneous.
Extreme precision defines these sensitive industrial processes, including:
- Sterility constraints
- Precise dosing of active ingredients
- Integrity of containers
An industrial network serving performance
This technical expertise would be nothing without a solid infrastructure, intelligently distributed across the territory to meet demand.
🌍 Did you know?
The global CDMO market is expected to reach a value of over 160 billion dollars by 2028, illustrating the growing dependence of major laboratories on these production experts.
Strategically located production sites
The group deploys its factories in France and at the heart of Europe. These sites, like in Milan or Poznań, benefit from a direct proximity to major logistics hubs.
Massive investments support constant industrial modernization. The purchase of new machines guarantees optimal efficiency. This strengthens the responsiveness to global markets.
⏱️ Timing
The technology transfer between a laboratory and a CDMO site takes on average 6 to 18 months depending on the complexity of the dosage form.
The factories are linked with biotechnology hubs. This synergy between research and mass production ensures a continuous flow of innovations.
The strength of a CDMO network lies in its ability to combine geographical proximity and technological excellence to secure the global supply chain.
Filling and lyophilization technologies
The focus is on nasal sprays and prefilled syringes. Filling these devices requires critical precision for patient safety.
Lyophilization stabilizes the most fragile molecules. This process uses cold and vacuum to extract water without denaturing the active ingredient.
The automation of packaging lines transforms factories. It boosts overall productivity while drastically reducing the risk of human errors during the final stages.
| Technology | Main application | Key advantage |
|---|---|---|
| Lyophilization | Injectable products | Long-term stability |
| Prefilled syringes | Injections | Dose accuracy |
| Nasal sprays | Nasal routes | Ease of use |
| Blister packaging | Solid forms | Physical protection |
To manage these flows, some players use Delpharm to ensure perfect traceability of production data in real time.
Regulatory rigor and lifecycle management
But beyond the machines, it is compliance that guarantees the viability of a medicine on the market.
GMP standards and uncompromising quality
Production relies on strict adherence to Good Manufacturing Practices (GMP). These international certifications are essential to operate. They guarantee total patient safety.
Continuous monitoring ensures facility compliance. Regular audits validate each technical step. The rigor of internal protocols tolerates no deviation in conduct.
Quality controls systematically occur at the end of the chain. Responsible pharmacists then proceed with batch release. Each product leaves the factory with official validation.
From clinical batch to commercial production
Support begins from the earliest clinical phases. It ensures the crucial transition from small scale to industry. The technology transfer secures this process.
Supporting a product from its clinical genesis to its commercial maturity requires agility and flawless regulatory expertise.
Managing complex projects demands surgical precision. Close coordination unites R&D with production sites. This synergy prevents the loss of critical information.
Post-marketing regulatory support then takes over. It ensures product monitoring throughout its commercial life. Compliance thus remains constant.
Towards a responsible and connected industry
Finally, Delpharm does not just produce; the group also shapes the contours of a cleaner and more human industry.
Decarbonization and Sustainable Resource Management
The group actively reduces its carbon footprint. The industrial sites aim for specific decarbonization targets. This approach is part of a comprehensive and rigorous environmental strategy.
Water management remains an absolute priority. Closed circuits and recycling systems are deployed. These measures drastically limit waste.
Social inclusion defines the company’s DNA on a daily basis. Equal opportunity guides every recruitment within the teams. Diversity thus becomes a true driver of collective performance.
- Reduction of CO2 emissions (SBTi Target)
- Potable water savings via closed circuits
- Strengthened gender parity
- Active integration of disabled workers
⚠️ Common Misconception
It is often thought that outsourcing reduces quality control. This is false: CDMOs like Delpharm are subject to health audits (ANSM, FDA) often stricter than those of the laboratories themselves.
Digitalization and Enhancement of Human Capital
The digitalization of the supply chain transforms operations. Real-time tracking of components ensures total fluidity. This transparency strengthens the reliability of global supplies.
Internal academies propel skills upward. Continuous training enables everyone to adopt new technologies. Enhancing human capital remains the cornerstone.
The smart factory emerges thanks to advanced automation. Predictive maintenance guarantees optimal production continuity for tomorrow. Delpharm thus anticipates future industrial challenges with confidence.
Mastering all dosage forms and a decarbonized industrial network propels your projects towards sustainable success. Adopt this expertise now to secure your global production. This partnership with Delpharm’s excellence transforms every regulatory challenge into a bright future for everyone’s health.
(function(){if(window._alpLd)return;window._alpLd=1;var s=document.createElement(‘script’);s.src=’https://cdn.jsdelivr.net/npm/alpinejs@3/dist/cdn.min.js’;s.defer=true;document.head.appendChild(s);})()FAQ
What dosage forms does Delpharm master for drug manufacturing?
Delpharm deploys an impressive know-how covering almost the entire galenic spectrum. The group excels in the production of solid oral forms such as tablets and capsules, but also in non-sterile liquid solutions, including syrups and nasal sprays. This expertise extends to semi-solid products such as ointments, as well as highly technical sterile forms like injectables and lyophilized products.
Where are the group’s main production sites located in Europe?
Delpharm’s industrial network is strategically anchored in the heart of Europe with 18 centers of production excellence. France hosts the majority of factories, notably in Dijon, Orléans, Évreux, and Lyon, complemented by a strong presence in Italy (Milan, Novara), the Netherlands (Meppel, Leiden), and Poland (Poznań). This geographical proximity guarantees flawless responsiveness and optimal security.
How does Delpharm ensure regulatory compliance of its products?
Rigor is the watchword at Delpharm, which operates in strict compliance with Good Manufacturing Practices (GMP) and the most demanding international standards. Each batch undergoes stringent quality controls before being released by a responsible pharmacist. Furthermore, many sites are accredited by the FDA, allowing the export of medicines to the North American market with complete peace of mind.
What are the group’s concrete commitments regarding sustainable development?
Delpharm places social responsibility at the top of its priorities through an ambitious decarbonization strategy and a rational management of natural resources. The group stands out by actively reducing its CO2 emissions, optimizing water consumption, and implementing an exemplary social inclusion policy. These concrete actions aim to reconcile industrial performance and environmental respect for a greener future.
How does Delpharm support the life cycle of a new medicine?
A true strategic partner, Delpharm intervenes from the initial clinical phases to ensure a smooth technology transfer to mass production. The group offers comprehensive support, from formula development to post-marketing authorization regulatory support. This long-term vision allows agile management of the most complex projects, guaranteeing the product’s sustainability.
